Merck has announced a pair of acquisitions. The company will acquire Santa Clara, CA-based Abmaxis, Inc. for $80 million in cash. Abmaxis is known for its antibody engineering technology platform, Abmaxis in-silico Immunization (AISIM), which enables structure-centric computational design followed by experimental selection of optimized human or humanized monoclonal antibodies. Merck will acquire 100% of the equity of Abmaxis, making Abmaxis a wholly owned subsidiary of Merck. In a larger t...